Conclusions: Cancer costs for employers are not uniformly increasing, but instead, shifting based on market competition and therapeutic innovation. Where costs are rising, they are driven by novel ...
Abbott, a global healthcare leader, announced the US commercial launch of SimpleScreen CRC, an FDA-approved blood-based colorectal cancer (CRC) screening test for adults age 45 and older who are at ...
Most prescriptions for specialty oral anticancer medications to treat blood cancers face initial insurer rejection, and even ...
ByDavid Wainer In the age of AI and gene sequencing, we still catch cancer one organ at a time. Only a handful of cancers ...
It’s that time of year when pink ribbons and tutus flood your newsfeed, commercial breaks, and health alerts. In the midst of ...
Today, the National Comprehensive Cancer Network® (NCCN®) published the first-ever edition of NCCN Clinical Practice ...
Open-source oncology tools span patient-facing trackers and explainers, genomics-to-therapy ranking systems, and LLMs ...
Abbott will sell Freenome’s SimpleScreen CRC test in the U.S. alongside the Cologuard Plus stool-based test it gained in the $21 billion acquisition of Exact Sciences.
AI-enabled digital pathology analysis shows aglatimagene significantly increased lymphocyte infiltration and immune engagement with tumor cells compared to standard-of-care radiotherapy alone two ...
Abbott (NYSE: ABT) today announced the U.S. commercial launch of SimpleScreen™ CRC, an FDA-approved blood-based colorectal cancer (CRC) screening test for adults age 45 and older who are at average ...
(“CelSiege”) has appointed BIOT, on a non-exclusive basis, as its authorized introduction and business development representative in Japan and the People’s Republic of China for IN01, a clinical-stage ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results